Prior to 1983, several landmark reports prepared the stage for a detailed description of the Antiphospholipid (Hughes) syndrome (APS). Formerly depicted as lupus-like, APS exhibits a wide spectrum of symptoms that overlap with Sjogren’s, Hashimoto, and other autoimmune diseases. In this review, we take a glimpse into the history of description of APS, discussing the events that led to its recognition as one of the most common autoimmune diseases and the enormous impact of that recognition in the rheumatology field.
LaurellA-BNilssonIM.Hypergammaglobulinemia, circulating anticoagulant, and biologic false positive Wassermann reaction: a study in two cases. J Lab Clin Med1957;
49: 694–707.
11.
FeinsteinDRapaportS.Acquired inhibitors of blood coagulation. Prog Hemost Thromb1972;
1: 75–95.
12.
RivardGSchiffmanSRapaportS.Cofactor of the “lupus anticoagulant”. Thromb Diath Haemorrh1974;
32: 554–563.
13.
ConleyCLHartmannRC.A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest1952;
31: 621–622.
ManoharanAGibsonLRushB, et al.
Recurrent venous thrombosis with a “lupus” coagulation inhibitor in the absence of systemic lupus. Aust N Z J Med1977;
7: 422–426.
17.
YinEGastonL. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemorrh1965;
14: 88–115.
18.
ExnerTRickardKKronenbergH.Studies on phospholipids in the action of a lupus coagulation inhibitor. Pathology1975;
7: 319–328.
19.
Jayakody ArachchillageDGreavesM.The chequered history of the antiphospholipid syndrome. Br J Haematol2014;
165: 609–617.
20.
PengoVThiagarajanPShapiroSHeineM.Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood1987;
70: 69–76.
21.
ThiagarajanPShapiroSDe MarcoL.Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest1980;
66: 397–405.
22.
HarrisEN.History of the antiphospholipid syndrome. Rev Colomb Reumatol2009;
16: 326–329.
23.
HarrisENBoeyMLMackworth-YoungCG, et al.
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet1983;
322: 1211–1214.
24.
LoizouSMcCreaJRudgeABoyleCHarrisE.Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol1985;
62: 738–745.
NilssonIMÅstedtBHednerUBerezinD.Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand1975;
197: 153–159.
27.
SoulierJBoffaM.Avortements à répétition, thromboses et anticoagulant circulant anti-thromboplastine. Nouv Presse Med1980;
9: 359.
28.
BoeyMColacoCGharaviAElkonKLoizouSHughesG.Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J (Clin Res Ed)1983;
287: 1021–1023.
29.
HughesG.Connective tissue disease and the skin. Clin Exp Dermatol1984;
9: 535–544.
30.
WilsonWHughesG.Aetiology of Jamaican neuropathy. Lancet (London, England)1975;
305: 345.
31.
WilsonWGharaviAKoikeT, et al.
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum1999;
42: 1309–1311.
32.
AshersonRMackworth-YoungCHarrisEGharaviAHughesG.Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE. Rheumatol Int1985;
5: 91–93.
33.
HarrisE.Syndrome of the black swan. Br J Rheumatol1987;
26: 324–326.
34.
Alarcón-SegoviaDDelezéMOriaCV, et al.
Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine (Baltimore)1989;
68: 353–365.
35.
AshersonRAKhamashtaMAOrdi-RosJ, et al.
The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore)1989;
68: 366–374.
36.
Mackworth-YoungCLoizouSWalportM.Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis1989;
48: 362–367.
GalliMBarbuiTComfuriusP, et al.
Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet1990;
335: 1544–1547.
39.
MatsuuraEIgarashiYFujimotoMIchikawaKKoikeT.Anticardiolipin cofactor (s) and differential diagnosis of autoimmune disease. Lancet1990;
336: 177–178.
40.
McNeilHSimpsonRChestermanCKrilisS.Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA1990;
87: 4120–4124.
HughesG.Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J (Clin Res Ed)1983;
287: 1088–1089.
43.
MiyakisSLockshinMDAtsumiT, et al.
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;
4: 295–306.
44.
Rodriguez-GarciaJLBertolacciniMLCuadradoMJSannaGAteka-BarrutiaOKhamashtaMA.Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called ‘seronegative APS’). Ann Rheum Dis2012;
71: 242–244.
KhamashtaMACuadradoMJMujicFTaubNAHuntBJHughesGR.The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med1995;
332: 993–997.
47.
RosoveMHBrewerPM.Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med1992;
117: 303–308.
48.
CrowtherMAGinsbergJSJulianJ, et al.
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med2003;
349: 1133–1138.
49.
FinazziGMarchioliRBrancaccioV, et al.
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1. J Thromb Haemost2005;
3: 848–853.
50.
Ruiz-IrastorzaGCuadradoMRuiz-ArruzaI, et al.
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies. Lupus2011;
20: 206–218.
51.
KeelingDBaglinTTaitC, et al.
Guidelines on oral anticoagulation with warfarin–fourth edition. Br J Haematol2011;
154: 311–324.
52.
TektonidouMGAndreoliLLimperM, et al.
EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis2019;
78: 1296–1304.
53.
CohenHHuntBJEfthymiouM, et al.
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol2016;
3: e426–e436.
54.
PengoVDenasGZoppellaroG, et al.
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood2018;
132: 1365–1371.
55.
AndradeDCerveraRCohenH, et al. 15th international congress on antiphospholipid antibodies task force on antiphospholipid syndrome treatment trends report. In: ErkanDLockshinMD (eds) Antiphospholipid syndrome: current research highlights and clinical insights.
Cham:
Springer International Publishing, 2017, pp.317–338.
56.
CerveraRPietteJCFontJ, et al.
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002;
46: 1019–1027.
57.
CerveraRRodríguez-PintóIColafrancescoS, et al.
14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome. Autoimmun Rev2014;
13: 699–707.
58.
GuelerFRongSGwinnerW, et al.
Complement 5a receptor inhibition improves renal allograft survival. J Am Soc Nephrol2008;
19: 2302–2312.
59.
FerraraDELiuXEspinolaRG, et al.
Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum2003;
48: 3272–3279.
60.
HalcoxJPDeanfieldJE.Beyond the laboratory: clinical implications for statin pleiotropy. Circulation2004;
109: II-42–8.
61.
FerraraDSwerlickRCasperK, et al.
Fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost2004;
2: 1558–1563.
62.
FirkinBHowardM.RadfordN. Possible relationship between lupus inhibitor and recurrent abortion in young women. Lancet1980;
316: 366.
63.
RaiRCliffordKCohenHReganL.High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod1995;
10: 3301–3304.
64.
LaskinCABombardierCHannahME, et al.
Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med1997;
337: 148–154.
65.
TrioloGFerranteACicciaF, et al.
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum2003;
48: 728–731.
66.
RaiRCohenHDaveMReganL.Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ1997;
314: 253–257.
67.
FarquharsonRGQuenbySGreavesM.Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol2002;
100: 408–413.
68.
RobertsonBGreavesM.Antiphospholipid syndrome: an evolving story. Blood Rev2006;
20: 201–212.
69.
EspinosaGCerveraR.Current treatment of antiphospholipid syndrome: lights and shadows. Nat Rev Rheumatol2015;
11: 586–596.
BatesSMGreerIAMiddeldorpSVeenstraDLPrabulosA-MVandvikPO.VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest2012;
141: e691S–e736S.
72.
ErkanDAguiarCLAndradeD, et al.
14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev2014;
13: 685–696.
73.
RuffattiATonelloMHoxhaA, et al.
Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study. Thromb Haemost2018;
47: 639–646.
74.
SciasciaSHuntBTalavera-GarciaELlisoGKhamashtaMCuadradoM.The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol2016;
214: 273.e1–.e8.
LefkouEMamopoulosADagklisTVosnakisCRoussoDGirardiG.Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J Clin Invest2016;
126: 2933–2940.
77.
RuffattiASalvanEDel RossT, et al.
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. Thromb Haemost2014;
112: 727–735.
78.
SteinkassererAEstallerCWeissESimRDayA.Complete nucleotide and deduced amino acid sequence of human beta 2-glycoprotein I. Biochem J1991;
277: 387–391.
79.
IoannouYPericleousCGilesILatchmanDSIsenbergDARahmanA.Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human β2‐glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum2007;
56: 280–290.
80.
AmigoMGarcia-TorresRRoblesMBochicchioTReyesP.Renal involvement in primary antiphospholipid syndrome. J Rheumatol1992;
19: 1181–1185.
81.
CanaudGBienaiméFTabarinF, et al.
Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med2014;
371: 303–312.
82.
HughsonMDMccartyGABrumbackRA.Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome. Hum Pathol1995;
26: 716–724.
83.
CanaudGBienaiméFViauA, et al.
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease. Nat Med2013;
19: 1288–1296.
84.
Montiel‐ManzanoGRomay‐PenabadZPapalardo de MartinezE, et al.
In vivo effects of an inhibitor of nuclear factor‐kappa B on thrombogenic properties of antiphospholipid antibodies. Ann N Y Acad Sci2007;
1108: 540–553.
85.
NishimuraMNiiTTrimovaG, et al.
The NF-κB specific inhibitor DHMEQ prevents thrombus formation in a mouse model of antiphospholipid syndrome. J Nephropathol2013;
2: 114–121.
86.
Vega‐OstertagMCasperKSwerlickRFerraraDHarrisENPierangeliSS.Involvement of p38 MAPK in the up‐regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum2005;
52: 1545–1554.
87.
Vega‐OstertagMHarrisENPierangeliSS.Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin. Arthritis Rheum2004;
50: 2911–2919.
88.
HughesGR.Hughes’ syndrome: the antiphospholipid syndrome. A historical view. Lupus1998;
7: 1–4.
89.
LacknerKJPeetzDvon LandenbergP.Revision of the Sapporo criteria for the antiphospholipid syndrome – coming to grips with evidence and Thomas Bayes?Thromb Haemost2006;
95: 917–919.
90.
LockshinMSammaritanoLSchwartzmanS.Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum2000;
43: 440–443.
91.
PietteJ.Towards improved criteria for the antiphospholipid syndrome. Lupus1998;
7: 149–157.
92.
RuffattiAOlivieriSTonelloM, et al.
Influence of different IgG anticardiolipin antibody cut‐off values on antiphospholipid syndrome classification. J Thromb Haemost2008;
6: 1693–1696.
93.
BertolacciniMLAmengualOAndreoliL, et al.
14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev2014;
13: 917–930.
